Citations

Citations to this article as recorded by  

• Neurologists’ decision-making in the management of generalised myasthenia gravis: Therapeutic inertia and treatment choices
  Gerardo Gutiérrez-Gutiérrez, Rocío Gómez-Ballesteros, Adrián Ares, Ramón Villaverde, Virginia Reyes, Thaís Armangué, Paola Díaz-Abós, Pablo Rebollo, Neus Canal, Luis Querol, Jorge Maurino, Elena Cortés-Vicente
  Journal of Neuromuscular Diseases.2026; 13(5): 1039.     CrossRef
• Identifying Provider Prescribing Practices for GLP‐1RAs and SGLT‐2is in Patients With Type 2 Diabetes to Address Pharmacoinequity
  Parnnate Wongsirisakul, Vincent L. Chen, Ponni V. Perumalswami, Piaopiao Li
  Journal of Diabetes Research.2026;[Epub]     CrossRef
• Assessing Clinical Inertia on Implementing Clinical Guideline Recommendations in Patients with Type 2 Diabetes: A Clinician Survey Study
  Judith Stephenson, Nancy Witkowski, Joseph Smith, Anny Wong, Lindsay Bengtson, Vincent Willey
  Diabetes, Metabolic Syndrome and Obesity.2026; Volume 19: 1.     CrossRef
• A Real-World Evaluation of Therapeutic Inertia in Patients with Severe Uncontrolled Chronic Obstructive Pulmonary Disease
  Myriam Calle Rubio, Juan José Soler-Cataluña, Pere Almagro, Arturo Huerta, Diego González-Segura, Borja Cosío
  International Journal of Chronic Obstructive Pulmonary Disease.2026; Volume 21: 1.     CrossRef
• Implementing SGLT2 Inhibitor Therapy in Line with the New NICE Guidelines for Type 2 Diabetes Management
  Philip Newland-Jones, Partha Kar, Beth Kelly, Rahul Mohan, Sarah Davies, Jane Diggle, Marc Evans, Kevin Fernando, Debbie Hicks, Naresh Kanumilli, Nicola Milne, Dipesh Patel, Samuel Seidu, Adie Viljoen, David C. Wheeler, John P. H. Wilding
  Diabetes Therapy.2026; 17(8): 1095.     CrossRef
• Initial conceptual development of a pilot questionnaire for patient-perceived clinical inertia in chronic disease management: an exploratory study with a predominantly Peruvian sample
  Jorge Isaac Necochea-Chamorro, Monica Elisa Meneses-La-Riva
  Frontiers in Health Services.2026;[Epub]     CrossRef
• Medication adherence: an overlooked critical determinant of pharmacological effectiveness
  Michel Burnier, Michel Azizi, Pankaj Gupta, Przemyslaw Kardas, Marie-Paule Schneider, Bernard Vrijens
  Pharmacological Reviews.2026; : 100161.     CrossRef
• Efficient and Effective Diabetes Care in the Era of Digitalization and Hypercompetitive Research Culture: A Focused Review in the Western Pacific Region with Malaysia as a Case Study
  Boon-How Chew, Pauline Siew Mei Lai, Dhashani A/P Sivaratnam, Nurul Iftida Basri, Geeta Appannah, Barakatun Nisak Mohd Yusof, Subashini C. Thambiah, Zubaidah Nor Hanipah, Ping-Foo Wong, Li-Cheng Chang
  Health Systems & Reform.2025;[Epub]     CrossRef
• Clinical control in COPD and therapeutic implications: The EPOCONSUL audit
  Myriam Calle Rubio, Marc Miravitlles, Juan José Soler Cataluña, José Luis López-Campos, Bernardino Alcázar Navarrete, Manuel E. Fuentes Ferrer, Juan Luis Rodríguez Hermosa, Stelios Loukides
  PLOS ONE.2025; 20(1): e0314299.     CrossRef
• Association between sex, age, temporal trends, and glycemic control of 221,769 adults with type 2 diabetes in a multi-ethnic middle-income Asian country
  Swee Hung Ang, Lee-Ling Lim, Feisul Idzwan Mustapha, Eliana Ahmad, Sanjay Rampal
  Diabetes Research and Clinical Practice.2025; 220: 111976.     CrossRef
• 3. Blood glucose-lowering therapies – Non-insulin options for type 2 diabetes
  Stephen Colagiuri, Antonio Ceriello
  Diabetes Research and Clinical Practice.2025; 222: 112147.     CrossRef
• Therapeutic inertia in statin therapy for secondary prevention after percutaneous coronary intervention: a nationwide population-based cohort study
  Young-Hoon Seo, Jee-Young Hong, Yong-Kyun Kim, Ki-Hong Kim, Taek-Geun Kwon, Jang-Ho Bae
  BMC Cardiovascular Disorders.2025;[Epub]     CrossRef
• Current Status of Delay in Injectable Therapy among Type 2 Diabetes Mellitus Patients in South Korea: Multicenter Retrospective Study (2015–2021)
  Jong Han Choi, Min Kyong Moon, Hae Jin Kim, Kyung Ae Lee, Hyun Jin Kim, Jung Hae Ko, Jae-Seung Yun, Seung-Hyun Ko, Suk Chon, Nam Hoon Kim
  Endocrinology and Metabolism.2025; 40(5): 727.     CrossRef
• Patient Perspectives of the Operationalization of Adult Patient–centred Care at the Primary Care Diabetes Support Program, London, Ontario: A Qualitative Descriptive Study
  Gillian Young, Anika Garg, Dana Ryan, Leslie Meredith, Stewart Harris, Sonja M. Reichert, Lindsay Hedden, Maria Mathews
  Canadian Journal of Diabetes.2025; 49(7): 381.     CrossRef
• Exploring the Evidence for Personalized Pharmacotherapy in Type 2 Diabetes—A Systematic Review
  Velimir Altabas, Jelena Marinković Radošević
  Journal of Personalized Medicine.2025; 15(11): 539.     CrossRef
• Obesity management from the perspectives of people living with obesity in Canada: A mixed‐methods study
  David C. W. Lau, Ian Patton, Reena Lavji, Adel Belloum, Ginnie Ng, Renuca Modi
  Diabetes, Obesity and Metabolism.2024; 26(4): 1529.     CrossRef
• Using continuous glucose monitoring to measure and improve quality metrics: Updates on the Healthcare Effectiveness Data and Information Set 2024 Glucose Management Indicator measure
  Marissa Morris-Murray, Marie Frazzitta
  Journal of Managed Care & Specialty Pharmacy.2024; 30(10-b Suppl): S30.     CrossRef
• Bridging the gap in cardiovascular care in diabetic patients: are cardioprotective antihyperglycemic agents underutilized?
  André J Scheen
  Expert Review of Clinical Pharmacology.2023; 16(11): 1053.     CrossRef

Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) are novel glucose-lowering therapies that have been shown to induce clinically significant reductions in body weight. However, this weight loss may not be attributed solely to fat mass (FM). Given the importance of skeletal muscle and lean body mass (LBM) on cardio-metabolic health and physical function, we reviewed the available literature reporting the effects of GLP-1RAs and SGLT2is on body composition. Results demonstrate that, in most circumstances, the weight loss associated with both therapies predominantly comprises a reduction in FM, although significant heterogeneity exists between studies. In over half of the studies identified, the proportion of LBM reduction ranged between 20% and 50% of total weight lost, which is consistent with diet-induced weight loss and bariatric surgery. No clear differences existed between GLP-1RAs and SGLT2is. Consequently, the loss of LBM and skeletal muscle associated with weight loss induced by GLP-1RAs and SGLT2is warrants attention. Strategies to preserve skeletal muscle and improve physical function, for example through structured exercise, are of great importance.

Citations

Citations to this article as recorded by  

• GPR75: A Newly Identified Receptor for Targeted Intervention in the Treatment of Obesity and Metabolic Syndrome
  Michael L. Fragner, Manish A. Parikh, Kaedrea A. Jackson, Michal Laniado Schwartzman, William H. Frishman, Stephen J. Peterson
  Cardiology in Review.2026; 34(4): 364.     CrossRef
• Narrative Review of Perioperative Glucagon-like Peptide-1 (GLP-1) Agonists in Spine Surgery
  James W. Connelly, Rajkishen Narayanan, Teeto Ezeonu, Parth Kothari, Nicholas Spina, William Ryan Spiker, Brandon Lawrence, Darrel S. Brodke, Gregory D. Schroeder, Brian A. Karamian
  Clinical Spine Surgery.2026; 39(2): 47.     CrossRef
• Mechanisms of insulin resistance in elderly sarcopenia patients and their bidirectional relationship
  Haiyan Du, Yuqing Qu, Zhouyang Huai, Shumin Wang
  Geriatric Nursing.2026; 69: 103907.     CrossRef
• Relevance and Safe Utilization of Amino Acids in Supplements for Human Nutrition: Lessons from Clinical and Preclinical Studies
  François Blachier
  Nutrients.2026; 18(2): 296.     CrossRef
• Semaglutide augments vascular proliferation and cardiac performance in a large animal model of ischemic cardiomyopathy
  Kelsey C. Muir, Christopher Stone, Dwight D. Harris, Meghamsh Kanuparthy, Mark Broadwin, Jad Hamze, Jun Feng, Frank W. Sellke
  American Journal of Physiology-Heart and Circulatory Physiology.2026; 330(3): H651.     CrossRef
• Body composition changes after 6 and 12 months of dietary weight loss: insights from the DIETFITS trial
  Sun H Kim, Ji Hye Heo, Kristen Cunanan, Christopher D Gardner
  Journal of the Endocrine Society.2026;[Epub]     CrossRef
• Advancing sarcopenia assessment with wearable and app-based technology: a scoping review
  Ayush Mehra, Justo Perez, Jessica L. Krok-Schoen, Roberto M. Benzo, Colleen K. Spees, Shang-Jui Wang, Steven K. Clinton, Stefan A. Czerwinski, Brett S. Nickerson
  The Journal of nutrition, health and aging.2026; 30(5): 100824.     CrossRef
• Obesity and Weight Management in HIV: Epidemiology, Complications, and Emerging Treatments
  Luke Pryke, John R. Koethe, Samuel Bailin
  Current HIV/AIDS Reports.2026;[Epub]     CrossRef
• Humans with function-disrupting variants in the myostatin gene (MSTN) have increased skeletal muscle mass and strength, and less adiposity
  Joseph L. Herman, Peter Dornbos, Karl Landheer, Benjamin J. Geraghty, Marc A. Egerman, Duc Phan, Mary Germino, Jason W. Mastaitis, Johnathon R. Walls, Luca A. Lotta, Gonçalo Abecasis, Aris Baras, Judith Y. Altarejos, Mark W. Sleeman, Olle Melander, Tea Sh
  Nature Communications.2026;[Epub]     CrossRef
• Type 2 diabetes mellitus
  Melanie J. Davies, Soo Lim, Tommy Slater, Jonathan Goldney, Athena Philis-Tsimikas, Denise R. Franco, Roberta Lamptey, Thomas Yates, Tsvetalina Tankova, Ildiko Lingvay
  Nature Reviews Disease Primers.2026;[Epub]     CrossRef
• Mitochondrial Adaptations in Skeletal Muscle Following Incretin‐Based Therapies: In Vitro
  Victoria Old, Melanie Davies, Matthew Denniff, Pratik Choudhary, Nicholas Eastley, Robert U. Ashford, Emma Watson
  Journal of Cachexia, Sarcopenia and Muscle.2026;[Epub]     CrossRef
• Prehabilitation in cardiac surgery: a state-of-the-art review
  Ben Gibbison, Maria Pufulete, Rebecca Maier, Enoch Akowuah
  Heart.2026; : heartjnl-2025-326769.     CrossRef
• Glucagon‐Like Peptide‐1 Receptor Agonism and Muscle Health: Vascular and Myocellular Effects on Glucose and Protein Metabolism
  Christos S. Katsanos, Zhenqi Liu, Philip J. Atherton
  Comprehensive Physiology.2026;[Epub]     CrossRef
• The onco-bariatric paradigm: a tri-phasic metabolic obesity framework for synergizing glucagon-like peptide-1 receptor agonists and metabolic bariatric surgery
  Dong Jin Park, Yoonhong Kim, Dongjae Jeon, Young Suk Park, Kyung Won Seo, Ki Hyun Kim
  Kosin Medical Journal.2026; 41(1): 3.     CrossRef
• Effect of Incretin-Based and Nonpharmacologic Weight Loss on Body Composition
  John A. Batsis, Alessandro Gavras, Danae C. Gross, C. Ray Cheever, Bruna R. Da Silva, Luiz Fernando Meira Filho, Emily P. Jones, Dakota Batchek, Simone Khandpekar, Rohan Patel, Bilal Awkal, Annamarie Pape, Marianne Bahna, Mauro Zamboni, Carla M. Prado
  Annals of Internal Medicine.2026; 179(7): 996.     CrossRef
• Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Complications Following Thoracic and/or Lumbar Spinal Fusion for Degenerative Spine Disease
  Arman Kishan, Harmon S. Khela, Nicolas L. Carayannopoulos, Manjot Singh, Lara Cohen, Zvipo Chisango, Kyriakos Chatzis, Peter S. Tretiakov, Shaleen Vira, Pawel P. Jankowski, Andrew J. Schoenfeld, Peter G. Passias, Alan H. Daniels
  Spine.2026; 51(9): E218.     CrossRef
• GLP-1 Receptor Agonist-Associated Weight Loss and Aesthetic Breast Surgery: A Narrative Review and Experience-Based Recommendations for Plastic and Reconstructive Surgeons
  Maurice Y Nahabedian, Anand K Deva, Deeba Ahmed, Paolo Fanzio, Jason Hammer
  Aesthetic Surgery Journal Open Forum.2026;[Epub]     CrossRef
• Biased agonists for the treatment of type 2 diabetes and obesity: a novel pharmacological paradigm edging closer to clinical reality?
  Ibrahim E. Hashem, Baha H. Abuajameia, Saghir Akhtar
  Journal of Drug Targeting.2026; : 1.     CrossRef
• LEAN mass Preservation with Resistance Exercise and Protein during semaglutide and tirzepatide therapy (LEAN-PREP study): a protocol for a randomised controlled trial
  Ameenah A Alawadhi, Dherar Alroudhan, Dalal J Alsaeed, Bashayer W Almarshad, Dalal H Alshehabi, Badreya A Allahou, Anant Mashankar, Ebaa Al Ozairi, Stuart Gray
  BMJ Open.2026; 16(4): e116911.     CrossRef
• Impact of GLP-1 receptor agonists on cardiovascular risk reduction in patients with obesity without type 2 diabetes mellitus: a systematic review
  Paquita del Rocío Quizhpe Donoso, Raffaele Francesco Zirufo Briones, Carmen Paola Montes Castro, Daniela Lorena Barros Narváez, Steven Ayala Velasco, Sara Noelia Cabrera Jimenez
  International Journal of Research in Medical Sciences.2026; 14(5): 2051.     CrossRef
• Safety of SGLT2 inhibitors for patients with type 2 diabetes: where are we now?
  André J. Scheen
  Expert Opinion on Drug Safety.2026; 25(10): 1819.     CrossRef
• Advantages of Skeletal Muscle Preservation in Settings of Weight Loss
  David J. Glass
  Aging Cell.2026;[Epub]     CrossRef
• Lean Mass Changes With Incretin Therapy Versus Lifestyle Intervention: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
  Naseem Eisa, Omar Barood
  Diabetes, Obesity and Metabolism.2026; 28(6): 4818.     CrossRef
• Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
  Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M Apovian, Shagun Bindlish, Jonathan Bonnet, W Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M Kane, Jasdeep Saluja, Deepa San
  Obesity Pillars.2026; 18: 100269.     CrossRef
• Gut-Derived FGF15 Modulates Lean Mass, Bone, and Bile Acid Responses to Weight Loss
  Nadejda Bozadjieva-Kramer, Garrett McMahon, Ziru Li, Jordan Wean, Jae Hoon Shin, Andriy Myronovych, Robert W. O’Rourke, Ormond A. MacDougald, Randy J. Seeley
  Diabetes.2026; 75(6): 938.     CrossRef
• The Role of Combining Exercise with Pharmacologic Management of Chronic Kidney disease: From Sodium-Glucose Co-Transporter-2 and Glucagon-Like Peptide-1 to Broader Therapeutic Strategies
  Thomas J. Wilkinson, Greg Biddle, Emily James
  Nephron.2026; 150(8): 533.     CrossRef
• Radiological assessment of body composition changes and complications in an era of incretin-based therapies: A narrative review
  Jonah Moyal, Benjamin Rehany
  University of Toronto Medical Journal.2026;[Epub]     CrossRef
• Preoperative Weight Loss Intervention With Glucagon-Like Peptides 1 Receptor Agonists Is Associated With Lower Complication Rates Following Primary Total Knee Arthroplasty Than Preoperative Bariatric Surgery
  George Bcharah, Austin E. Wininger, Zaid Elsabbagh, Collin L. Braithwaite, Paul R. Van Schuyver, Mark J. Spangehl, Henry D. Clarke, Joshua S. Bingham
  Arthroplasty Today.2026; 39: 102033.     CrossRef
• GLP-1 Agonist Use Is Not Associated With a Reduction of Paraspinal Muscle Quality in Diabetic Patients With Low Back Pain: A Retrospective Cohort Study
  Arman T. Zadeh, Erika Chiapparelli, Krizia Amoroso, Ali E. Guven, Jiaqi Zhu, Paul Kohli, Bruno Verna, Anna-Maria Mielke, Jennifer Shue, Marco D. Burkhard, Andrew A. Sama, Federico P. Girardi, Frank P. Cammisa, Alexander P. Hughes
  HSS Journal®: The Musculoskeletal Journal of Hospital for Special Surgery.2026; 22(4): 343.     CrossRef
• Beyond diabetes and obesity: GLP-1 receptor agonists as multifunctional therapeutics across the steatotic liver disease spectrum
  Sundararajan Mahalingam, Kusum K. Kharbanda, Carol A. Casey, Karuna Rasineni
  Frontiers in Pharmacology.2026;[Epub]     CrossRef
• Associations Between Weight Loss Prior to Knee and Hip Arthroplasty and Peri‐ and Post‐Operative Outcomes: A Systematic Review and Meta‐Analysis
  Moneet Gill, Tim Lindsay, Daniel Kevin Llanera, Tricia M.‐M. Tan, Alex Liddle, Chioma Izzi‐Engbeaya
  Obesity Reviews.2026;[Epub]     CrossRef
• Impact of GLP-1/GIP Therapy and Nutrition Counseling on Body Composition
  Peter Gillespie, Kathryn Hoffman, Candace Smith
  The Journal of Nutrition.2026; : 101618.     CrossRef
• Body composition changes in patients on GLP-1 receptor agonists undergoing an intensive cardiac rehabilitation program
  Ian Jennings, Kristine Ly, Mariam Marooki, Marissa Dzotsi, Gavin McLaren, Raphael E Cuomo, Shady Abohashem, Pam R Taub
  European Journal of Preventive Cardiology.2026;[Epub]     CrossRef
• Effects of Semaglutide on Body Composition and GFR
  Hiddo J.L. Heerspink, Maria Soler, Jelle M. Beernink, Niels Jongs, Secundino Cigarran, Josep M. Cruzado, Maria Jesús Puchades, Marina López-Martínez, Ellen Apperloo, Femke Waanders, Gozewijn D. Laverman, Annemarie van der Aart-van der Beek, André P. van B
  Clinical Journal of the American Society of Nephrology.2026; 21(7): 1149.     CrossRef
• Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial
  Richard E. Pratley, Douglas Scott Denham, Rupal Trivedi, Elaine Watkins, Lisa Connery, Jennifer Barnes, Dongzi Yu, Janet Hong, Christopher Simard, Kimberly Umans, Lan Liu, Giridhar S. Tirucherai, Jing L. Marantz
  Nature Medicine.2026; 32(7): 2673.     CrossRef
• The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists and Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials
  Rishi Jobanputra, Jack A. Sargeant, Tatiana Plekhanova, Emily James, Abdullah Almaqhawi, David R. Webb, Melanie J. Davies, Thomas Yates
  Diabetes/Metabolism Research and Reviews.2026;[Epub]     CrossRef
• Invited State of the Art Review for MCP Rethinking Obesity Beyond Body Mass Index: A Review of Body Composition and Chronic Disease Risk
  Jason R. Jaggers, Madison Kindred, Ryan Porter, Xuemei Sui, Carl J. Lavie, Vivek K. Prasad
  Mayo Clinic Proceedings.2026;[Epub]     CrossRef
• Strategies for Optimizing Heart Failure Care in the Older Adult: A Scientific Statement From the American Heart Association
  Sabra C. Lewsey, Trejeeve Martyn, Vanessa Blumer, Nicholas K. Brownell, Quin E. Denfeld, Shannon M. Dunlay, Parag Goyal, Shannon Halloway, Daniel Matlock, Orly Vardeny, Harriette G.C. Van Spall
  Circulation.2026;[Epub]     CrossRef
• Glucagon‐Like Peptide‐1 Receptor Agonist‐Based Agents and Body Composition: Filling MoreGaps
  Robert L. Dubin, Tierra N. Sanders, Hunter M. Schwab, Steven B. Heymsfield, Frank L. Greenway
  Obesity.2026; 34(S2): 51.     CrossRef
• Real-World Body Composition and Blood Pressure Changes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation: A Causal Inference Study of Connected Device Data
  Agathe Chabassier, Benjamin Vittrant, Pierre Binon, Erwan Scornet, Julie Josse
  Mayo Clinic Proceedings: Digital Health.2026; 4(3): 100375.     CrossRef
• Efficacy and Safety of Bimagrumab in Adults With Obesity and Metabolic Dysfunction: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
  Chuhan Shao, Hanmo Lin, Jie Yu, Haiyan Chen, Yaolin Ren, Jing Ren, Yuan Zeng, Yifan Wu, Qian Zhang, Xinhua Xiao
  Diabetes, Obesity and Metabolism.2026; 28(10): 9433.     CrossRef
• Muscle in fat trouble: The rise of IMAT in metabolic and musculoskeletal disease
  Vanessa M. Weik, Andreas L. Birkenfeld, Andreas Peter, Cora Weigert, Simon I. Dreher
  Molecular Metabolism.2026; 111: 102424.     CrossRef
• Imeglimin Attenuates Skeletal Muscle Atrophy in Mouse Models of Obesity and Ageing
  Yangli Ye, Diandian Qian, Ikumi Nomura, Naoki Kobayashi, Yukiko Shimizu, Tadashi Okamura, Motoharu Awazawa, Kohjiro Ueki
  Journal of Cachexia, Sarcopenia and Muscle.2026;[Epub]     CrossRef
• Practical considerations for the use of incretin mimetics in patients with neuroendocrine neoplasms: An expert consensus statement
  Udhayvir S. Grewal, Po H. Ear, Mohamad B. Sonbol, Andrew M. Bellizzi, Johannes Hofland, Joakim Crona, Joseph S. Dillon, Jennifer A. Chan, James R. Howe, Jonathan Strosberg, Simron Singh, Thorvardur R. Halfdanarson
  Cancer.2026;[Epub]     CrossRef
• GLP-1 receptor agonists as multisystem therapies: from glycemic control to cardiorenal, neuroimmune, and metabolic disease
  Malek Zarei, Yasamin Hajiani
  Diabetology & Metabolic Syndrome.2026;[Epub]     CrossRef
• The hallmarks of skeletal muscle health
  Anna Vainshtein, Bert Blaauw, Katrien De Bock, Pura Munoz-Canoves, Eric N. Olson, Coen A. C. Ottenheijm, Erik A. Richter, Jorge L. Ruas, Laurent Schaffer, Bruce Spiegelman, Marco Sandri
  Nature Metabolism.2026; 8(9): 1843.     CrossRef
• Low baseline HbA1c and reduced eGFR are associated with relatively unfavorable body recomposition after SGLT2 inhibitor therapy in type 2 diabetes
  Mizuki Gobaru, Nao Hasuzawa, Noboru Kurinami, Nobuhiko Wada, Lixiang Wang, Ayako Nagayama, Kenji Ashida, Yoshinori Moriyama, Hideaki Jinnouchi, Masatoshi Nomura
  Frontiers in Endocrinology.2026;[Epub]     CrossRef
• 2026 ESC Guidelines on cardiac rehabilitation
  Maria Bäck, Matthias Wilhelm, Thimo Marcin, Felipe V C Machado, Anna Sandberg, Sergio Buccheri, Almudena Castro Conde, Michal Czapla, Salvatore De Rosa, Irene Gibson, Anežka Gombošová, Oleksii Korzh, Maria Teresa La Rovere, Emanuela Teresina Locati, Josep
  European Heart Journal.2026;[Epub]     CrossRef
• Biological Pathways of Strength Preservation During Calorie Restriction‐Induced Weight Loss Among Adults Without Obesity
  Nadia Moore, Akshay Bareja, Leanna M. Ross, Katherine A. Collins‐Bennett, Susan B. Racette, Leanne M. Redman, Corby K. Martin, Sai Krupa Das, Calen P. Ryan, Daniel W. Belsky, William E. Kraus, Kim M. Huffman
  Obesity.2026; 34(10): 1892.     CrossRef
• 2026 ESC Guidelines on cardiac rehabilitation
  Maria Bäck, Matthias Wilhelm, Thimo Marcin, Felipe V C Machado, Anna Sandberg, Sergio Buccheri, Almudena Castro Conde, Michal Czapla, Salvatore De Rosa, Irene Gibson, Anežka Gombošová, Oleksii Korzh, Maria Teresa La Rovere, Emanuela Teresina Locati, Josep
  European Journal of Preventive Cardiology.2026;[Epub]     CrossRef
• A Case Report of a Novel Myelin Protein Zero (MPZ) Pathogenic Variant in Charcot–Marie–Tooth Disease Combined With Type 2 Diabetes
  Lu Xia, Liyan Cai, Xin Chen, Kun Zhou, Wei Huang, Yuanyuan Zhu, Shinian Yang, Neetu Rawal
  Case Reports in Genetics.2026;[Epub]     CrossRef
• Strengthening muscle for healthy ageing: innovative treatments for sarcopenia
  Sara Ancel, Emmeran Le Moal, Yu Xin Wang, Helen M. Blau
  Nature Reviews Drug Discovery.2026;[Epub]     CrossRef
• Precision medicine in patients with rare forms of genetic obesity: necessity for coordinated and structured care
  Karine Clément, I Sadaf Farooqi, Peter Kühnen, Martin Wabitsch, Metin Cetiner, Jesús Argente, Annette Grueters
  The Journal of Clinical Endocrinology & Metabolism.2026;[Epub]     CrossRef
• Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
  Melanie J. Davies, Vanita R. Aroda, Mandeep Bajaj, Nuha A. ElSayed, Francesco Giorgino, Jennifer Green, Rita R. Kalyani, Nisa M. Maruthur, Chantal Mathieu, Sylvia E. Rosas, Peter Rossing, Tommy Slater, Tsvetalina Tankova, Pinar Topsever, Apostolos Tsapas,
  Diabetologia.2026;[Epub]     CrossRef
• Weight Loss or Muscle Loss? Cellular Mechanisms and Clinical Strategies for Preserving Lean Mass During GLP‐1‐Based Therapy
  Esma Sukurica, Goksemin F. Sengul, Fatma Uysal Cinar
  Diabetes, Obesity and Metabolism.2026;[Epub]     CrossRef
• Effects of caloric restriction with different doses of exercise on fat loss in people living with type 2 diabetes: A secondary analysis of the DOSE-EX randomized clinical trial
  Mark P.P. Lyngbæk, Grit E. Legaard, Nina S. Nielsen, Cody Durrer, Thomas P. Almdal, Morten Asp Vonsild Lund, Benedikte Liebetrau, Caroline Ewertsen, Carsten Lauridsen, Thomas P.J. Solomon, Kristian Karstoft, Bente K. Pedersen, Mathias Ried-Larsen
  Journal of Sport and Health Science.2025; 14: 100999.     CrossRef
• Worldwide burden of antidiabetic drug-induced sarcopenia: An international pharmacovigilance study
  Jaehyun Kong, Seoyoung Park, Tae Hyeon Kim, Jae E. Lee, Hanseul Cho, Jiyeon Oh, Sooji Lee, Hyesu Jo, Hayeon Lee, Kyeongmin Lee, Jaeyu Park, Louis Jacob, Damiano Pizzol, Sang Youl Rhee, Sunyoung Kim, Dong Keon Yon
  Archives of Gerontology and Geriatrics.2025; 129: 105656.     CrossRef
• Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH)
  Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal
  Nature Reviews Drug Discovery.2025; 24(3): 171.     CrossRef
• Medically Tailored Meals in Heart Failure: A Systematic Review of the Literature, 2013-2023
  NATHALIE MCINTOSH, HAYLEY BILLINGSLEY, SCOTT L. HUMMEL, WHITNEY L. MILLS
  Journal of Cardiac Failure.2025; 31(6): 939.     CrossRef
• Medical Weight Management Considerations in Plastic Surgery
  Alisha B. Paranzino, Brittany Vieira, Caroline M. Apovian, Shailesh Agarwal
  Plastic & Reconstructive Surgery.2025; 155(1): 207.     CrossRef
• GLP1Ra‐based therapies and DXA‐acquired musculoskeletal health outcomes: a focused meta‐analysis of placebo‐controlled trials
  Kristen M. Beavers, Tiffany M. Cortes, Colleen M. Foy, Lauren Dinkla, Fernando Reyes San Martin, Jamy D. Ard, Monica C. Serra, Daniel P. Beavers
  Obesity.2025; 33(2): 225.     CrossRef
• Sodium-dependent glucose transporter 2 inhibitors improve heart function in patients with type 2 diabetes and heart failure
  Yi-Fei Zhang, Yu-Xiang Liu, Wu-Xiao Yang
  World Journal of Cardiology.2025;[Epub]     CrossRef
• The Effects of Glucagon‐Like Peptide‐1 Receptor Agonists on Mitochondrial Function Within Skeletal Muscle: A Systematic Review
  Victoria J. Old, Melanie J. Davies, Dimitris Papamargaritis, Pratik Choudhary, Emma L. Watson
  Journal of Cachexia, Sarcopenia and Muscle.2025;[Epub]     CrossRef
• Pharmacologic Management of Heart Failure with Preserved Ejection Fraction (HFpEF) in Older Adults
  Ashkan Hashemi, Min Ji Kwak, Parag Goyal
  Drugs & Aging.2025; 42(2): 95.     CrossRef
• Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
  Areesha Moiz, Kristian B. Filion, Helia Toutounchi, Michael A. Tsoukas, Oriana H.Y. Yu, Tricia M. Peters, Mark J. Eisenberg
  Annals of Internal Medicine.2025; 178(2): 199.     CrossRef
• Hypoglycemic drugs and sarcopenia
  Yu. A. Dolgikh, S. V. Bulgakova, D. P. Kurmaev, E. V. Treneva, O. V. Kosareva, P. Ya. Merzlova, L. A. Sharonova, A. S. Bulgakov
  Experimental and Clinical Gastroenterology.2025; (8): 216.     CrossRef
• Resistance Exercise in Treating Heart Failure with Preserved Ejection Fraction (HFpEF) and Obesity: Targeting Skeletal Muscle Abnormalities and Ectopic Adipose Depots
  Daniel J. McDonough
  Physiologia.2025; 5(1): 10.     CrossRef
• Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes?
  Amina A. Al-Awadi, Stuart R. Gray, Ebaa Al-Ozairi
  Reviews in Endocrine and Metabolic Disorders.2025; 26(5): 857.     CrossRef
• Challenges, current innovations, and opportunities for managing type 2 diabetes in frail older adults: a position paper of the European Geriatric Medicine Society (EuGMS)—Special Interest Group in Diabetes
  Virginia Boccardi, Gülistan Bahat, Cafer Balci, Isabelle Bourdel-Marchasson, Antoine Christiaens, Lorenzo Maria Donini, Sibel Cavdar, Stefania Maggi, Serdar Özkök, Tajana Pavic, Stany Perkisas, Stefano Volpato, Muhammad Shoaib Zaidi, Andrej Zeyfang, Alan
  European Geriatric Medicine.2025; 16(4): 1231.     CrossRef
• Exploring the Potential Effect of GLP1R Agonism on Common Aging-Related Diseases via Glucose Reduction: A Mendelian Randomization Study
  Wei Jiang, Kaixi Ding, Maoyi Yang, Zhipeng Hu, Rensong Yue, Lewis A Lipsitz
  The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences.2025;[Epub]     CrossRef
• Metabolic dysfunction-associated steatotic liver disease in adults
  Daniel Q. Huang, Vincent W. S. Wong, Mary E. Rinella, Jerome Boursier, Jeffrey V. Lazarus, Hannele Yki-Järvinen, Rohit Loomba
  Nature Reviews Disease Primers.2025;[Epub]     CrossRef
• Body composition changes during weight reduction with tirzepatide in the SURMOUNT‐1 study of adults with obesity or overweight
  Michelle Look, Julia P. Dunn, Robert F. Kushner, Dachuang Cao, Charles Harris, Theresa Hunter Gibble, Adam Stefanski, Ryan Griffin
  Diabetes, Obesity and Metabolism.2025; 27(5): 2720.     CrossRef
• Longitudinal association of SGLT2 inhibitors and GLP-1RAs on falls in persons with type 2 diabetes
  Yasuhiro Suzuki, Hiroaki Suzuki, Kazushi Maruo, Takaaki Matsuda, Yuki Murayama, Yoko Sugano, Yoshinori Osaki, Hitoshi Iwasaki, Motohiro Sekiya, Yasushi Hada, Hitoshi Shimano
  Scientific Reports.2025;[Epub]     CrossRef
• Non-invasive vestibular nerve stimulation (VeNS) reduces visceral adipose tissue: results of a randomised controlled trial
  Erik Viirre, Julie Sittlington, David Wing, Ruth Price, Caomhan Logue, Daniel Moreno, Jeff Ledford-Mills, Cynthia Knott, Carel W. le Roux, David Grieve, Sinead Watson, Jason McKeown, Paul D. McGeoch
  Scientific Reports.2025;[Epub]     CrossRef
• Role of GLP‑1 receptor agonists in sepsis and their therapeutic potential in sepsis‑induced muscle atrophy (Review)
  Xuan Zhao, Yukun Liu, Dongfang Wang, Tonghan Li, Zhikai Xu, Zhanfei Li, Xiangjun Bai, Yuchang Wang
  International Journal of Molecular Medicine.2025; 55(5): 1.     CrossRef
• Effect of liraglutide biosimilar vs. reference liraglutide on weight reduction in T2DM patients with obesity: post hoc analysis of phase III trial
  Sujoy Ghosh, Bipin Sethi, Sanjay Kalra, Manash P. Baruah, Abhishek Mane, Sanjay Choudhari, Anup Petare, Mayur Jadhav, Saiprasad Patil, Hanmant Barkate
  Cardiovascular Diabetology – Endocrinology Reports.2025;[Epub]     CrossRef
• Effectiveness of tele‐guidance for physiotherapy in older patients with type 2 diabetes: A randomized controlled trial
  Hiroaki Kataoka, Takuo Nomura, Hiroyuki Oka, Yukio Ikeda
  Journal of Diabetes Investigation.2025; 16(7): 1284.     CrossRef
• How do glucagon‐like Peptide‐1 receptor agonists affect measures of muscle mass in individuals with, and without, type 2 diabetes: A systematic review and meta‐analysis
  Oluwaseun Anyiam, Arash Ardavani, Rushdina Sofia Abdul Rashid, Avinash Panesar, Iskandar Idris
  Obesity Reviews.2025;[Epub]     CrossRef
• Changes in body composition and handgrip strength during dapagliflozin administration in patients with chronic kidney disease
  Takahiro Yajima, Kaoru Noda, Kumiko Yajima
  Clinical Kidney Journal.2025;[Epub]     CrossRef
• Exercise for Postmenopausal Bone Health – Can We Raise the Bar?
  Shejil Kumar, Cassandra Smith, Roderick J. Clifton-Bligh, Belinda R. Beck, Christian M. Girgis
  Current Osteoporosis Reports.2025;[Epub]     CrossRef
• Mechanosensitive Channels Mediate Pancreatic β Cells Reactive Oxygen Species Formation and Downregulation of Essential Genes During Therapeutic Ultrasound Treatment
  Mallory Brayer, Vesna Zderic, Aleksandar Jeremic
  Journal of Ultrasound in Medicine.2025; 44(9): 1577.     CrossRef
• Navigating Sarcopenia Risks in GLP-1RA Therapy for Advanced Heart Failure
  Winston Wang, Danielle Green, Ramzi Ibrahim, Mahmoud Abdelnabi, Hoang Nhat Pham, Beani Forst, Mohamed Allam, Patrick Sarkis, George Bcharah, Juan Farina, Chadi Ayoub, Dan Sorajja, Reza Arsanjani
  Biomedicines.2025; 13(5): 1108.     CrossRef
• Aerobic, resistance, and specialized exercise training in heart failure with preserved ejection fraction: A state-of-the-art review
  Saeid Mirzai, Uttsav Sandesara, Mark J. Haykowsky, Peter H. Brubaker, Dalane W. Kitzman, Anthony E. Peters
  Heart Failure Reviews.2025; 30(5): 1015.     CrossRef
• The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care
  Andrew Gatto, Kevin Liu, Nesa Milan, Stephanie Wong
  Current Reviews in Musculoskeletal Medicine.2025; 18(10): 469.     CrossRef
• GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates
  Jason W. Mastaitis, Daniel Gomez, José G. Raya, Diana Li, Soo Min, Michael Stec, Sandra Kleiner, Toya McWilliams, Judith Y. Altarejos, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman
  Nature Communications.2025;[Epub]     CrossRef
• Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus
  Christopher S. Walker, Jacqueline F. Aitken, Greeshma Vazhoor Amarsingh, Shaoping Zhang, Garth J. S. Cooper
  Nature Reviews Endocrinology.2025; 21(8): 482.     CrossRef
• Obesity medications in patients with recurrent weight gain or suboptimal clinical response following bariatric surgery: a meta-analysis
  Mahdieh Golzarand, Karamollah Toolabi, Parvin Mirmiran
  International Journal of Obesity.2025; 49(9): 1676.     CrossRef
• Exploring the disconnect: mechanisms underpinning the absence of physical function improvement with SGLT2 inhibitors
  Cian Sutcliffe, Jack A. Sargeant, Thomas Yates, Melanie J. Davies, Luke A. Baker
  Frontiers in Systems Biology.2025;[Epub]     CrossRef
• Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
  Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M Apovian, Shagun Bindlish, Jonathan Bonnet, W Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M Kane, Jasdeep Saluja, Deepa San
  The American Journal of Clinical Nutrition.2025; 122(1): 344.     CrossRef
• Nutritional priorities to support GLP‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society
  Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa
  Obesity.2025; 33(8): 1475.     CrossRef
• Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
  Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa
  American Journal of Lifestyle Medicine.2025;[Epub]     CrossRef
• Targeting intramyocellular lipids to improve aging muscle function
  David W. Russ, Ravikumar Manickam, Srinivas M. Tipparaju
  Lipids in Health and Disease.2025;[Epub]     CrossRef
• Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society
  Dariush Mozaffarian, Monica Agarwal, Monica Aggarwal, Lydia Alexander, Caroline M. Apovian, Shagun Bindlish, Jonathan Bonnet, W. Scott Butsch, Sandra Christensen, Eugenia Gianos, Mahima Gulati, Alka Gupta, Debbie Horn, Ryan M. Kane, Jasdeep Saluja, Deepa
  Obesity Pillars.2025; 15: 100181.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonist Medications Alter Outcomes of Spine Surgery
  Joshua M. Wiener, Parshva A. Sanghvi, Katelyn Vlastaris, Thomas Mroz, Jonathan Belding, David C. Kaelber, Thomas Olson, Kevin P. Francis, John S. Adams, Nicholas Bernthal, William L. Sheppard
  Spine.2025; 50(13): 871.     CrossRef
• Ultra-processed food consumption is associated with knee osteoarthritis: Data from the Osteoarthritis Initiative
  Zehra Akkaya, Wynton M. Sims, John A. Lynch, Maximilian T. Löffler, Felix Gassert, Michael Nevitt, Charles E. McCulloch, Nancy E. Lane, Valentina Pedoia, Katharina Ziegeler, Thomas M. Link, Gabby B. Joseph
  Osteoarthritis and Cartilage.2025; 33(9): 1130.     CrossRef
• Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists: A retrospective observational study
  W. Scott Butsch, Suela Sulo, Andrew T. Chang, Jeeyun A. Kim, Kirk W. Kerr, Dominique R. Williams, Refaat Hegazi, Thadchaigeni Panchalingam, Scott Goates, Steven B. Heymsfield
  Obesity Pillars.2025; 15: 100186.     CrossRef
• Lifestyle Interventions for Treatment and Remission of Type 2 Diabetes and Prediabetes in Adults: A Clinical Practice Guideline From the American College of Lifestyle Medicine
  Richard M. Rosenfeld, Meagan L. Grega, Micaela C. Karlsen, Abd Moain Abu Dabrh, R. Nisha Aurora, Jonathan P. Bonnet, Lori Donnell, Stephanie L. Fitzpatrick, Beth Frates, Elizabeth A. Joy, Jane F. Kapustin, Dawn R. Noe, Gunadhar Panigrahi, Arun Ram, Lianna
  American Journal of Lifestyle Medicine.2025;[Epub]     CrossRef
• Serum uric acid reduction through SGLT2 inhibitors: evidence from a systematic review and meta-analysis
  Shiwen Yang, Qiaozhi Hu, Kexin Liu, Binjie Xiao, Bofei Zhang, Na Su
  Frontiers in Pharmacology.2025;[Epub]     CrossRef
• GLP-1 receptor agonists, body composition, skeletal muscle and risk of sarcopaenia: from promising findings in animal models to debated concern in human studies
  André J. Scheen
  Diabetes & Metabolism.2025; 51(5): 101681.     CrossRef
• Incretin Receptor Agonism, Fat-free Mass, and Cardiorespiratory Fitness: A Narrative Review
  Zhenqi Liu, Nathan R Weeldreyer, Siddhartha S Angadi
  The Journal of Clinical Endocrinology & Metabolism.2025; 110(10): 2709.     CrossRef
• Redefining obesity: beyond body mass index
  Javed Butler, Francesco Fioretti, Melanie J Davies
  European Heart Journal.2025; 46(38): 3758.     CrossRef
• Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects
  Jessica Chadwick, Colin Berry, Meredith A. Carpenter, Geeta Gulati, Siri Lagethon Heck, Michael A. Hinterberg, Rury R. Holman, Matthew M.Y. Lee, Torbjørn Omland, Clare Paterson, Mark C. Petrie, Naveed Sattar, Svati H. Shah, Sama Shrestha, Harald Sourij, E
  The Journal of Clinical Pharmacology.2025; 65(11): 1460.     CrossRef
• Emerging evidence and potential avenues to achieve durable outcomes in patients with obesity: the confluence of nutrition, and Microbiome on body composition
  Dra. M. Isabel T. D. Correia, Nitin Kapoor, Emma Chávez-Manzanera, Luís Henrique Wolff Gowdak, Amira Al Kharusi, Felipe F. Casanueva, Bruno Halpern, Gary Frost, Raed Aldahash
  Reviews in Endocrine and Metabolic Disorders.2025; 26(5): 745.     CrossRef
• Pattern of Antidiabetic Drug Prescription in Older Persons With Type 2 Diabetes: Results From the German DPV Registry
  Andrej Zeyfang, Stefan Gölz, Federica Iraci, Christian Wagner, Christian Scheer, Thomas Kubiak, Latife Bozkurt, Martin Heni, Reinhard W. Holl
  Journal of the American Medical Directors Association.2025; 26(8): 105724.     CrossRef
• GLP-1 Receptor Agonists in Spine Surgery: Current Evidence and Future Directions
  Luis M. Salazar, Samuel Alfonsi, Vincent P. Federico, Arash Sayari
  Contemporary Spine Surgery.2025; 26(8): 1.     CrossRef
• The expanding role of GLP-1 receptor agonists: a narrative review of current evidence and future directions
  Areesha Moiz, Kristian B. Filion, Michael A. Tsoukas, Oriana H.Y. Yu, Tricia M. Peters, Mark J. Eisenberg
  eClinicalMedicine.2025; 86: 103363.     CrossRef
• The Potential of SARMs and Antimyostatin Agents in Addressing Lean Body Mass Loss From GLP‐1 Agonists: A Literature Review
  Jimmy Wen, Ubaid Ansari, Mouhamad Shehabat, Zaid Ansari, Burhaan Syed, Adam Razick, Daniel Razick, Muzammil Akhtar, Eldo Frezza
  Journal of Diabetes.2025;[Epub]     CrossRef
• Harnessing Facebook to Investigate Real-World Mentions of Adverse Events of Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications: Observational Study of Facebook Posts From 2022 to 2024
  Amrutha S Alibilli, Vidur Jain, Heran Mane, Xiaohe Yue, Alexandria Ratzki-Leewing, Junaid S Merchant, Shaniece Criss, Quynh C Nguyen, Rozalina G McCoy, Thu T Nguyen
  JMIR Infodemiology.2025; 5: e73619.     CrossRef
• Effects of Blood-Glucose Lowering Therapies on Body Composition and Muscle Outcomes in Type 2 Diabetes: A Narrative Review
  Ioana Bujdei-Tebeică, Doina Andrada Mihai, Anca Mihaela Pantea-Stoian, Simona Diana Ștefan, Claudiu Stoicescu, Cristian Serafinceanu
  Medicina.2025; 61(8): 1399.     CrossRef
• Discovery of pan-EphB tyrosine kinase inhibitor for metabolic syndrome sparing EphB3 signaling in mice
  Syed Tareq, Heba A. Ewida, Sumaih Zoubi, Harrison Benson, Dhavalkumar Patel, Hanin Diab, Souvik Patra, Daniela Redrovan, Ehsan Nozohouri, Taysa Berivan Bassani, Alisson Campos Cardoso, Kofi Frimpong-Manson, Lida Khodavirdilou, Md Tareq Aziz, Jenny L. Wilk
  Pharmacological Research.2025; 219: 107900.     CrossRef
• Mortality Risk of Sarcopenia and Malnutrition in Older Patients with Type 2 Diabetes Mellitus
  Shinta Yamamoto, Yoshitaka Hashimoto, Fuyuko Takahashi, Ryosuke Sakai, Yuto Saijo, Chihiro Munekawa, Hanako Nakajima, Noriyuki Kitagawa, Rieko Nakatani, Takafumi Osaka, Hiroshi Okada, Naoko Nakanishi, Saori Majima, Emi Ushigome, Masahide Hamaguchi, Michia
  Nutrients.2025; 17(16): 2622.     CrossRef
• Glucagon-like peptide-1 receptor agonists and muscle mass effects
  Alexandr Ceasovschih, Andreea Asaftei, Maria Giovanna Lupo, Stanislav Kotlyarov, Hana Bartušková, Anastasia Balta, Victorita Sorodoc, Laurentiu Sorodoc, Maciej Banach
  Pharmacological Research.2025; 220: 107927.     CrossRef
• Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
  Yong-ho Lee, Soo Lim, Melanie J. Davies
  Nature Reviews Endocrinology.2025; 21(12): 783.     CrossRef
• The Pharmacist's Role in the Use of Incretin‐Based Therapies for Weight Management: An Opinion of the Endocrine and Metabolism Practice and Research Network of the American College of Clinical Pharmacy
  Sara Lingow, Nicholas Carris, Jennifer Clements, Lindsay Courtney, Abby Lennon, Christina H. Sherrill, Elizabeth Van Dril
  JACCP: JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY.2025; 8(10): 1078.     CrossRef
• KYLO-0603, a novel liver-targeting, thyroid hormone receptor-β agonist for the inhibition of MASH progression
  Xueqin lu, Shengjun Wang, Yanchun Du, Bixian Xie, Qingyan Chen, Jinzhen Lin, Bailing Chen, Kunyuan Cui, Hanbing Li,
  PLOS One.2025; 20(9): e0331768.     CrossRef
• GLP-1 receptor agonists and sarcopenia: Weight loss at a cost? A brief narrative review
  Dimitrios Pantazopoulos, Evanthia Gouveri, Dimitrios Papazoglou, Nikolaos Papanas
  Diabetes Research and Clinical Practice.2025; 229: 112924.     CrossRef
• Frailty and Effects of Semaglutide in Obesity-Related HFpEF
  Ambarish Pandey, Dalane W. Kitzman, Khaja M. Chinnakondepalli, Shachi Patel, Barry A. Borlaug, Javed Butler, Melanie J. Davies, Sanjiv J. Shah, Subodh Verma, Cecilia Rönnbäck, Anne Domdey, Karoline Liisberg, Morten Schou, Eduardo Perna, Fozia Z. Ahmed, Mi
  JACC: Heart Failure.2025; 13(10): 102610.     CrossRef
• Cannabis improves metabolic dysfunction and macrophage signatures in obese mice
  Brandon N. VanderVeen, Thomas D. Cardaci, Christian A. Unger, Mitchell M. NeSmith, Jeffrey C. Freeman, Arianna V. Bastian, Kasie Roark, Mansi Upadhyay, Andrew G. Levy, Brooke M. Bullard, Sierra J. McDonald, Kandy T. Velázquez, Reilly T. Enos, Jason L. Kub
  American Journal of Physiology-Cell Physiology.2025; 329(4): C1316.     CrossRef
• Thermogenic Targets for Obesity Management in the Era of Incretin-Based Therapies
  Sahar Soliman, Rebecca Andrews-Dickert, Petra Rocic, Mihail Mitov
  Pharmaceuticals.2025; 18(10): 1519.     CrossRef
• Agonistes du récepteur du GLP-1 et sarcopénie : question émergente ou véritable enjeu clinique ?
  Serge Halimi
  Médecine des Maladies Métaboliques.2025; 19(8): 593.     CrossRef
• Glucagon-like peptide-1 receptor agonists and muscle health: potential role in sarcopenia prevention and treatment
  Ainhoa González-Luis, Vicente Llinares-Arvelo, Carlos E Martínez-Alberto, Carolina Hernández-Carballo, Carmen Mora-Fernández, Juan F Navarro-González, Javier Donate-Correa
  European Journal of Endocrinology.2025; 193(5): R31.     CrossRef
• Effects of Semaglutide in Obesity-Related Heart Failure with Preserved Ejection Fraction Across the Age Spectrum: Findings from the STEP-HFpEF Programme
  Ambarish Pandey, Michael Moroney, Subodh Verma, Barry A. Borlaug, Javed Butler, Melanie J. Davies, Dalane W. Kitzman, Sanjiv J. Shah, Mark C. Petrie, Cecilia Rönnbäck, Anne Domdey, Søren Rasmussen, Khaja M. Chinnakondepalli, Shachi Patel, Mikhail N. Kosib
  European Journal of Heart Failure.2025; 27(11): 2537.     CrossRef
• Clinician Guidance on the Benefits of Healthy Nutrition and Increased Physical Activity for People With Type 2 Diabetes Following Glucagon-Like Peptide 1 Receptor Agonist Initiation
  Pamela Kushner, Carlos Campos, Aaron King, Davida F. Kruger, Javier Morales
  Clinical Diabetes.2025; 43(5): 681.     CrossRef
• Preserving the Metabolic Engine: Muscle as the Therapeutic Target for Cardiovascular Prevention in Obesity Pharmacotherapy
  Fabian Sanchis-Gomar, Ian J. Neeland, Pilar Ruiz-Lozano, Osama Alnahar, Fatima Rodriguez
  Current Cardiology Reports.2025;[Epub]     CrossRef
• Sarcopenia and obesity: Two sides of the same coin. Incretin technologies in addressing the problem
  T. Yu. Demidova, K. A. Tolmacheva, S. A. Prilepa
  FOCUS. Endocrinology.2025; 6(4): 43.     CrossRef
• The role of glucagon-like peptides in osteosarcopenia
  Enaya Tufail, Somali Sanyal, Ambrish Mithal, Sabyasachi Sanyal, Naibedya Chattopadhyay
  Journal of Endocrinology.2025;[Epub]     CrossRef
• Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation
  Cody Rutledge, Angela Enriquez, Kevin Redding, Mabel Lopez, Steven Mullett, Stacy L. Gelhaus, Michael Jurczak, Eric Goetzman, Brett A. Kaufman
  Cardiovascular Drugs and Therapy.2024; 38(6): 1289.     CrossRef
• Drug‐related sarcopenia as a secondary sarcopenia
  Masafumi Kuzuya
  Geriatrics & Gerontology International.2024; 24(2): 195.     CrossRef
• Exercise induces tissue-specific adaptations to enhance cardiometabolic health
  Stephen P. Ashcroft, Ben Stocks, Brendan Egan, Juleen R. Zierath
  Cell Metabolism.2024; 36(2): 278.     CrossRef
• Once-weekly semaglutide administered after laparoscopic sleeve gastrectomy: Effects on body weight, glycemic control, and measured nutritional metrics in Japanese patients having both obesity and type 2 diabetes
  Rieko Kanai, Sachiho Kinoshita, Izumi Kanbe, Mariko Sameda, Shuhei Yamaoka, Osamu Horikawa, Yasuhiro Watanabe, Ichiro Tatsuno, Kohji Shirai, Takashi Oshiro, Atsuhito Saiki
  Obesity Pillars.2024; 9: 100098.     CrossRef
• Twenty‐four‐hour physical behaviour profiles across type 2 diabetes mellitus subtypes
  Joseph Henson, Aikaterina Tziannou, Alex V. Rowlands, Charlotte L. Edwardson, Andrew P. Hall, Melanie J. Davies, Thomas Yates
  Diabetes, Obesity and Metabolism.2024; 26(4): 1355.     CrossRef
• The Current Landscape of Pharmacotherapies for Sarcopenia
  Gulistan Bahat, Serdar Ozkok
  Drugs & Aging.2024; 41(2): 83.     CrossRef
• Malnutrition and Sarcopenia as Reasons for Caution with GLP-1 Receptor Agonist Use in HFpEF
  ELISSA DRIGGIN, PARAG GOYAL
  Journal of Cardiac Failure.2024; 30(4): 610.     CrossRef
• Is the GLP-1 receptor agonist, semaglutide, a good option for weight loss in persons with HIV?
  Daniel Lee, Jacqueline Capeau
  AIDS.2024; 38(4): 603.     CrossRef
• Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis
  Xin‐Hui Pan, Bryan Tan, Yip Han Chin, Ethan Cheng Zhe Lee, Gwyneth Kong, Bryan Chong, Martin Kueh, Chin Meng Khoo, Anurag Mehta, Priyanka Majety, Gowtham R. Grandhi, Georgios K. Dimitriadis, Roger Foo, Nicholas W. S. Chew, Carel W. Le Roux, Mamas A. Mamas
  Obesity.2024; 32(5): 840.     CrossRef
• Glucagon-Like Peptide-1 Receptor Agonists and Sodium Glucose Cotransporter-2 Inhibitors and Cardiorespiratory Fitness Interaction
  David Ni, Peter Kokkinos, Eric S Nylen
  Military Medicine.2024; 189(11-12): 2369.     CrossRef
• Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
  Robert M. Gutgesell, Rubén Nogueiras, Matthias H. Tschöp, Timo D. Müller
  Diabetes Therapy.2024; 15(5): 1069.     CrossRef
• The effects of myosteatosis on skeletal muscle function in older adults
  Kathleen Dondero, Ben Friedman, Julie Rekant, Rian Landers‐Ramos, Odessa Addison
  Physiological Reports.2024;[Epub]     CrossRef
• Preservation of healthy lean body mass and function during weight loss
  T. J. Wilkinson, D. Papamargaritis, J. A. King, J. A. Sargeant, C. Sutcliffe, L. A. Baker, S. Taheri, T. Yates, M. J. Davies
  Clinical Obesity.2024;[Epub]     CrossRef
• The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis
  Emanuela Talamonti, Jelena Davegardh, Anastasia Kalinovich, Sten M.M. van Beek, Nodi Dehvari, Carina Halleskog, Hamza M. Bokhari, Dana S. Hutchinson, Seungmin Ham, Laura J. Humphrys, Nicola C. Dijon, Aikaterini Motso, Anna Sandstrom, Evelyn Zacharewicz, I
  Molecular Metabolism.2024; 85: 101931.     CrossRef
• Core Trainee Prize Winner: Weight loss drugs: their role and potential future in orthopaedic surgery
  Tom Doyle
  Bone & Joint 360.2024; 13(3): 12.     CrossRef
• Challenges and opportunities in the management of type 2 diabetes in patients with lower extremity peripheral artery disease: a tailored diagnosis and treatment review
  Guillaume Mahé, Victor Aboyans, Emmanuel Cosson, Kamel Mohammedi, Gabrielle Sarlon-Bartoli, Damien Lanéelle, Tristan Mirault, Patrice Darmon
  Cardiovascular Diabetology.2024;[Epub]     CrossRef
• Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies
  Ian J. Neeland, Jennifer Linge, Andreas L. Birkenfeld
  Diabetes, Obesity and Metabolism.2024; 26(S4): 16.     CrossRef
• Changes in body weight and composition, metabolic parameters, and quality of life in patients with type 2 diabetes treated with subcutaneous semaglutide in real-world clinical practice
  Paola Pantanetti, Giovanni Cangelosi, Sara Alberti, Sandra Di Marco, Grazia Michetti, Gianluca Cerasoli, Marco Di Giacinti, Silvia Coacci, Nadia Francucci, Fabio Petrelli, Giuseppe Ambrosio, Roberto Grinta
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Decoding the Implications of Glucagon-like Peptide-1 Receptor Agonists on Accelerated Facial and Skin Aging
  Zainab Ridha, Sabrina Guillen Fabi, Raheel Zubair, Steven H Dayan
  Aesthetic Surgery Journal.2024; 44(11): NP809.     CrossRef
• Second Generation Anti-Obesity Medications
  Sri Nikhita Chimatapu, Steven D. Mittelman, Vibha Singhal
  Current Pediatrics Reports.2024; 12(4): 138.     CrossRef
• Metabolic effects of very-low calorie diet, Semaglutide, or combination of the two, in individuals with type 2 diabetes mellitus
  Oluwaseun Anyiam, Bethan Phillips, Katie Quinn, Daniel Wilkinson, Kenneth Smith, Philip Atherton, Iskandar Idris
  Clinical Nutrition.2024; 43(8): 1907.     CrossRef
• Dietary intake by patients taking GLP-1 and dual GIP/GLP-1 receptor agonists: A narrative review and discussion of research needs
  Sandra Christensen, Katie Robinson, Sara Thomas, Dominique R. Williams
  Obesity Pillars.2024; 11: 100121.     CrossRef
• Gut-muscle communication links FGF19 levels to the loss of lean muscle mass following rapid weight loss
  Jordan Wean, Salisha Baranwal, Nicole Miller, Jae Hoon Shin, Robert W. O'Rourke, Charles F. Burant, Randy J. Seeley, Amy E. Rothberg, Nadejda Bozadjieva-Kramer
  Diabetes & Metabolism.2024; 50(5): 101570.     CrossRef
• The Effects of Imeglimin on Muscle Strength in Patients with Type 2 Diabetes: A Prospective Cohort Study
  Takeshi Oyanagi, Shin Kawanabe, Hidekazu Tsukiyama, Ami Nishine, Yuta Nakamura, Tomoko Nakagawa, Mayuko Kanou, Juri Kubota, Shingo Tsunemi, Kenichi Yokota, Masakatsu Sone
  Diabetes Therapy.2024; 15(11): 2323.     CrossRef
• Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes
  Lidiya Kukova, Kashif M. Munir, Ahmed Sayeed, Stephen N. Davis
  Expert Opinion on Drug Metabolism & Toxicology.2024; 20(10): 939.     CrossRef
• Sarcopenia
  Avan A. Sayer, Rachel Cooper, Hidenori Arai, Peggy M. Cawthon, Marie-Josiane Ntsama Essomba, Roger A. Fielding, Miranda D. Grounds, Miles D. Witham, Alfonso J. Cruz-Jentoft
  Nature Reviews Disease Primers.2024;[Epub]     CrossRef
• Glucagon‐like peptide‐1 receptor agonist‐based agents and weight loss composition: Filling the gaps
  Robert L. Dubin, Steven B. Heymsfield, Eric Ravussin, Frank L. Greenway
  Diabetes, Obesity and Metabolism.2024; 26(12): 5503.     CrossRef
• Geriatric Pharmacotherapy Case Series: Medications for Diabetes—A Focus on Secondary Stroke Prevention
  Sabrina Warren, Shayla McKee, Erin Yakiwchuk
  The Senior Care Pharmacist.2024; 39(10): 350.     CrossRef
• Effectiveness and Side Effect Incidence in a Real-World Digital Weight-Loss Service Using Compounded Semaglutide: A Retrospective Comparative Study
  Louis Talay, Matt Vickers
  Obesities.2024; 4(4): 399.     CrossRef
• Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?
  Jennifer Linge, Andreas L. Birkenfeld, Ian J. Neeland
  Circulation.2024; 150(16): 1288.     CrossRef
• Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health during Weight Loss with New Generation Anti-Obesity Medications
  Gregory J Grosicki, Nikhil V Dhurandhar, Jessica L Unick, Shawn M Arent, J Graham Thomas, Holly Lofton, Madelyn C Shepherd, Jessica Kiel, Christopher Coleman, Satya S Jonnalagadda
  Current Developments in Nutrition.2024; 8(11): 104486.     CrossRef
• Malnutrition in patients with obesity: An overview perspective
  Cagney Cristancho, Kris M. Mogensen, Malcolm K. Robinson
  Nutrition in Clinical Practice.2024; 39(6): 1300.     CrossRef
• Changes in 24-Hour Urine Chemistry in Patients with Nephrolithiasis during Weight Loss with Glucagon-Like Peptide 1–Based Therapies
  Karen Feghali, Xilong Li, Naim M. Maalouf
  Kidney360.2024; 5(11): 1706.     CrossRef
• Nutritional Supplementation to Preserve Healthy Lean Mass and Function During Periods of Pharmacological and Nonpharmacological‐Induced Weight Loss: Protocol for a Systematic Review and Meta‐Analysis
  Emily James, Ryan J. Kelsey, Jack A. Sargeant, Joe Henson, Tom Yates, Thomas J. Wilkinson
  Health Science Reports.2024;[Epub]     CrossRef
• Semaglutide Improves Myocardial Perfusion and Performance in a Large Animal Model of Coronary Artery Disease
  Christopher R. Stone, Dwight D. Harris, Mark Broadwin, Meghamsh Kanuparthy, Ju-Woo Nho, Keertana Yalamanchili, Jad Hamze, M. Ruhul Abid, Frank W. Sellke
  Arteriosclerosis, Thrombosis, and Vascular Biology.2024;[Epub]     CrossRef
• Spotlight on the Mechanism of Action of Semaglutide
  Ilias Papakonstantinou, Konstantinos Tsioufis, Vasiliki Katsi
  Current Issues in Molecular Biology.2024; 46(12): 14514.     CrossRef
• Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Body Composition and Fluid Status in Cardiovascular Rehabilitation Patients with Coronary Artery Disease and Heart Failure
  José C. De La Flor, Blanca Coto Morales, Elena Basabe, María Rey Hernandez, Rocío Zamora González-Mariño, Celia Rodríguez Tudero, Irwing Benites Flores, Carlos Espinoza, Michael Cieza Terrones, Secundino Cigarrán Guldris, Jesús Hernández Vaquero
  Medicina.2024; 60(12): 2096.     CrossRef
• Malnutrition in real-world patients hospitalized for heart failure with preserved ejection fraction and its potential impact on generalizability of EMPEROR-Preserved trial
  Shinsuke Takeuchi, Takashi Kohno, Ayumi Goda, Yasuyuki Shiraishi, Mike Saji, Yuji Nagatomo, Toshikazu D. Tanaka, Makoto Takei, Shintaro Nakano, Kyoko Soejima, Shun Kohsaka, Tsutomu Yoshikawa
  International Journal of Cardiology.2023; 370: 263.     CrossRef
• Marked weight loss on liraglutide 3.0 mg: Real‐life experience of a Swiss cohort with obesity
  Sara Santini, Nathalie Vionnet, Jérôme Pasquier, Elena Gonzalez‐Rodriguez, Montserrat Fraga, Nelly Pitteloud, Lucie Favre
  Obesity.2023; 31(1): 74.     CrossRef
• Early type 2 diabetes treatment intensification with glucagon‐like peptide‐1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence
  Roy Rasalam, Sarah Abdo, Gary Deed, Richard O'Brien, Jane Overland
  Diabetes, Obesity and Metabolism.2023; 25(4): 901.     CrossRef
• The effects of weight‐lowering pharmacotherapies on physical activity, function and fitness: A systematic review and meta‐analysis of randomized controlled trials
  Rishi Jobanputra, Jack A. Sargeant, Abdullah Almaqhawi, Ehtasham Ahmad, Franciskos Arsenyadis, David R. Webb, Louisa Y. Herring, Kamlesh Khunti, Melanie J. Davies, Thomas Yates
  Obesity Reviews.2023;[Epub]     CrossRef
• Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial
  Rasmus M. Sandsdal, Christian R. Juhl, Simon B. K. Jensen, Julie R. Lundgren, Charlotte Janus, Martin B. Blond, Mads Rosenkilde, Adrian F. Bogh, Lasse Gliemann, Jens-Erik B. Jensen, Charalambos Antoniades, Bente M. Stallknecht, Jens J. Holst, Sten Madsbad
  Cardiovascular Diabetology.2023;[Epub]     CrossRef
• Impact of novel glucose‐lowering therapies on physical function in people with type 2 diabetes: A systematic review and meta‐analysis of randomised placebo‐controlled trials
  Ehtasham Ahmad, Franciskos Arsenyadis, Abdullah Almaqhawi, Mary Barker, Rishi Jobanputra, Jack A. Sargeant, David R. Webb, Thomas Yates, Melanie J. Davies
  Diabetic Medicine.2023;[Epub]     CrossRef
• Cancer cachexia as a blueprint for treating obesity
  Nikolai P. Jaschke, Tilman D. Rachner
  Trends in Endocrinology & Metabolism.2023; 34(7): 395.     CrossRef
• The sun is rising on a new era of pharmacotherapy for obesity: some words of caution
  Peter N. Benotti, Bruce R. Bistrian
  Surgery for Obesity and Related Diseases.2023; 19(9): 1075.     CrossRef
• Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
  Sha Zhang, Zhan Qi, Yidong Wang, Danfei Song, Deqiu Zhu
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Cysteine‐lowering treatment with mesna against obesity: Proof of concept and results from a human phase I, dose‐finding study
  Kathrine J. Vinknes, Thomas Olsen, Hasse Khiabani Zaré, Nasser E. Bastani, Emma Stolt, Anja F. Dahl, Roger D. Cox, Helga Refsum, Kjetil Retterstøl, Anders Åsberg, Amany Elshorbagy
  Diabetes, Obesity and Metabolism.2023; 25(11): 3161.     CrossRef
• Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia – A Narrative Review
  Miles D. Witham, Antoneta Granic, Ewan Pearson, Sian M. Robinson, Avan A. Sayer
  Drugs & Aging.2023; 40(8): 703.     CrossRef
• Introduction to the dietary management of obesity in adults
  Vivian Lee
  Clinical Medicine.2023; 23(4): 304.     CrossRef
• Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY)
  Daisuke Yabe, Kosuke Shiki, Gosuke Homma, Thomas Meinicke, Yuji Ogura, Yutaka Seino
  Diabetes, Obesity and Metabolism.2023; 25(12): 3538.     CrossRef
• Independent Link Between Use of Mineralocorticoid Receptor Antagonists and Muscle Wasting in Heart Failure Patients Not Receiving Renin-Angiotensin System Inhibitors
  Ryo Numazawa, Satoshi Katano, Toshiyuki Yano, Ryohei Nagaoka, Katsuhiko Ohori, Hidemichi Kouzu, Suguru Honma, Yusuke Fujisawa, Kotaro Yamano, Arata Osanami, Masayuki Koyama, Akiyoshi Hashimoto, Masato Furuhashi
  Circulation Journal.2023; 88(1): 10.     CrossRef
• Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
  Baris Afsar, Rengin Elsurer Afsar
  Clinical Nutrition.2023; 42(12): 2338.     CrossRef
• Oral semaglutide improves body composition and preserves lean mass in patients with type 2 diabetes: a 26-week prospective real-life study
  Sara Volpe, Giuseppe Lisco, Margherita Fanelli, Davide Racaniello, Valentina Colaianni, Valentina Lavarra, Domenico Triggiani, Lucilla Crudele, Vincenzo Triggiani, Carlo Sabbà, Giovanni De Pergola, Giuseppina Piazzolla
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• The Effects of Sodium–Glucose Cotransporter 2 Inhibitors on Body Composition in Type 2 Diabetes Mellitus: A Narrative Review
  Soodeh Jahangiri, Mojtaba Malek, Sanjay Kalra, Mohammad E. Khamseh
  Diabetes Therapy.2023; 14(12): 2015.     CrossRef
• Relationship between sodium–glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis
  Chengdong Xia, Yufeng Han, Chunhui Yin, Ruyue Geng, Zhenfei Liu, Yongle Du, Mingkun Yu
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• The Role of Lifestyle Modification with Second-Generation Anti-obesity Medications: Comparisons, Questions, and Clinical Opportunities
  Thomas A. Wadden, Ariana M. Chao, Molly Moore, Jena S. Tronieri, Adam Gilden, Anastassia Amaro, Sharon Leonard, John M. Jakicic
  Current Obesity Reports.2023; 12(4): 453.     CrossRef
• Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
  Giuseppe Lisco, Olga Eugenia Disoteo, Anna De Tullio, Vincenzo De Geronimo, Vito Angelo Giagulli, Fabio Monzani, Emilio Jirillo, Renato Cozzi, Edoardo Guastamacchia, Giovanni De Pergola, Vincenzo Triggiani
  Nutrients.2023; 16(1): 63.     CrossRef
• Novel Antidiabetic Strategies and Diabetologists' Views in Nonalcoholic Steatohepatitis
  Sabine Kahl, Jennifer Pützer, Michael Roden
  Seminars in Liver Disease.2022; 42(01): 048.     CrossRef
• Effect of Empagliflozin Versus Placebo on Body Fluid Balance in Patients With Acute Myocardial Infarction and Type 2 Diabetes Mellitus: Subgroup Analysis of the EMBODY Trial
  Yu Hoshika, Yoshiaki Kubota, Kosuke Mozawa, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu-Ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Jun Tanabe, Wataru
  Journal of Cardiac Failure.2022; 28(1): 56.     CrossRef
• Effect of GLP-1 receptor agonist, liraglutide, on muscle in spontaneously diabetic torii fatty rats
  Shohei Yamada, Yuji Ogura, Kazuho Inoue, Jun Tanabe, Takeshi Sugaya, Keiichi Ohata, Yoshio Nagai, Yasunori Natsuki, Seiko Hoshino, Shiika Watanabe, Daisuke Ichikawa, Kenjiro Kimura, Yugo Shibagaki, Atsuko Kamijo-Ikemori
  Molecular and Cellular Endocrinology.2022; 539: 111472.     CrossRef
• Exendin-4 alleviates steatosis in an in vitro cell model by lowering FABP1 and FOXA1 expression via the Wnt/-catenin signaling pathway
  Olfa Khalifa, Neyla S. AL-Akl, Khaoula Errafii, Abdelilah Arredouani
  Scientific Reports.2022;[Epub]     CrossRef
• Body composition changes at 12 months following different surgical weight loss interventions in adults with obesity: A systematic review and meta‐analysis of randomized control trials
  Amy Sylivris, Jakub Mesinovic, David Scott, Paul Jansons
  Obesity Reviews.2022;[Epub]     CrossRef
• Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
  Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Hristo Lliev, Atsutaka Yasui
  Expert Opinion on Drug Safety.2022; 21(10): 1315.     CrossRef
• Safety and effectiveness of empagliflozin according to body mass index in Japanese patients with type 2 diabetes: a subgroup analysis of a 3-year post-marketing surveillance study
  Kohei Kaku, Kazuhiro Yamamoto, Yumiko Fukushima, Seiko Mizuno, Daisuke Nitta
  Expert Opinion on Drug Safety.2022; 21(11): 1411.     CrossRef
• Le risque de dénutrition chez le sujet âgé diabétique : une limite à l’utilisation des « nouvelles » classes thérapeutiques ?
  Lyse Bordier, Jean Doucet, Bernard Bauduceau
  Médecine des Maladies Métaboliques.2022; 16(5): 422.     CrossRef
• Emerging evidence of the relationship between fat-free mass and ghrelin, glucagon-like peptide-1, and peptide-YY
  Austin J. Graybeal, Jada L. Willis, Elisa Morales-Marroquin, Grant M. Tinsley, Sarah E. Messiah, Meena Shah
  Nutrition.2022; 103-104: 111815.     CrossRef
• The Effectiveness of GLP-1 Receptor Agonist Semaglutide on Body Composition in Elderly Obese Diabetic Patients: A Pilot Study
  Yoshinori Ozeki, Takayuki Masaki, Akari Kamata, Shotaro Miyamoto, Yuichi Yoshida, Mitsuhiro Okamoto, Koro Gotoh, Hirotaka Shibata
  Medicines.2022; 9(9): 47.     CrossRef
• Distribution of lean mass and mortality risk in patients with type 2 diabetes
  Li Ding, Yuxin Fan, Jingting Qiao, Jing He, Ruodan Wang, Qing He, Jingqiu Cui, Zhongshu Ma, Fangqiu Zheng, Hua Gao, Chenlin Dai, Hongyan Wei, Jun Li, Yuming Cao, Gang Hu, Ming Liu
  Primary Care Diabetes.2022; 16(6): 824.     CrossRef
• Cardio-sarcopenia: A syndrome of concern in aging
  De Rong Loh, Ru-San Tan, Wee Shiong Lim, Angela S. Koh
  Frontiers in Medicine.2022;[Epub]     CrossRef
• Type 2 diabetes
  Ehtasham Ahmad, Soo Lim, Roberta Lamptey, David R Webb, Melanie J Davies
  The Lancet.2022; 400(10365): 1803.     CrossRef
• Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors
  Satoshi Katano, Toshiyuki Yano, Hidemichi Kouzu, Ryohei Nagaoka, Ryo Numazawa, Kotaro Yamano, Yusuke Fujisawa, Katsuhiko Ohori, Nobutaka Nagano, Takefumi Fujito, Ryo Nishikawa, Wataru Ohwada, Masaki Katayose, Tatsuya Sato, Atsushi Kuno, Masato Furuhashi
  Cardiovascular Diabetology.2022;[Epub]     CrossRef
• An overview of anamorelin as a treatment option for cancer-associated anorexia and cachexia
  Guilherme Wesley Peixoto Da Fonseca, Stephan von Haehling
  Expert Opinion on Pharmacotherapy.2021; 22(7): 889.     CrossRef
• Liraglutide Does Not Adversely Impact Fat‐Free Mass Loss
  Andrew Grannell, William P. Martin, Babak Dehestani, Werd Al‐Najim, John C. Murphy, Carel W. le Roux
  Obesity.2021; 29(3): 529.     CrossRef
• Rationale and design of the EMPA-ELDERLY trial: a randomised, double-blind, placebo-controlled, 52-week clinical trial of the efficacy and safety of the sodium–glucose cotransporter-2 inhibitor empagliflozin in elderly Japanese patients with type 2 diabet
  Daisuke Yabe, Kosuke Shiki, Keiko Suzaki, Thomas Meinicke, Yutaro Kotobuki, Kenichiro Nishida, Douglas Clark, Atsutaka Yasui, Yutaka Seino
  BMJ Open.2021; 11(4): e045844.     CrossRef
• Cancer Risk in Normal Weight Individuals with Metabolic Obesity: A Narrative Review
  Bethina Liu, Hugh E. Giffney, Rhonda S. Arthur, Thomas E. Rohan, Andrew J. Dannenberg
  Cancer Prevention Research.2021; 14(5): 509.     CrossRef
• Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
  Khaoula Errafii, Neyla S. Al-Akl, Olfa Khalifa, Abdelilah Arredouani
  Journal of Translational Medicine.2021;[Epub]     CrossRef
• Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus
  Vaneza Lira W. Wolf, Ikaro Breder, Luiz Sérgio F. de Carvalho, Alexandre A. S. Soares, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Sheila T. Kimura-Medorima, Wilson Nadruz, Gil Guerra-Júnior, Thiago Quinaglia, Elza Muscelli, Andrei C. Sposito
  Nutrition & Diabetes.2021;[Epub]     CrossRef
• Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors
  Marc Evans, Angharad R. Morgan, Zaheer Yousef, Gethin Ellis, Umesh Dashora, Dipesh C. Patel, Pam Brown, Wasim Hanif, Johnathan N. Townend, Naresh Kanumilli, Jim Moore, John P. H. Wilding, Stephen C. Bain
  Drugs.2021; 81(11): 1243.     CrossRef
• Glucose-lowering Drugs and Hospitalization for Heart Failure: A Systematic Review and Additive-effects Network Meta-analysis With More Than 500 000 Patient-years
  Riobaldo M Cintra, Ana Claudia Nogueira, Isabella Bonilha, Beatriz M Luchiari, Otavio R Coelho-Filho, Otavio R Coelho, Pedro Schwartzmann, Elza Muscellie, Wilson Nadruz, Luiz Sergio F Carvalho, Andrei C Sposito
  The Journal of Clinical Endocrinology & Metabolism.2021; 106(10): 3060.     CrossRef
• Physical activity and exercise in the management of type 2 diabetes: where to start?
  Deirdre Harrington, Joe Henson
  Practical Diabetes.2021; 38(5): 35.     CrossRef
• Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes
  
  New England Journal of Medicine.2021; 385(22): 2105.     CrossRef
• Effects of Antidiabetic Drugs on Muscle Mass in Type 2 Diabetes Mellitus
  Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Fujiwara, Kazuya Murata
  Current Diabetes Reviews.2021; 17(3): 293.     CrossRef
• Relationship between serum bilirubin concentration and sarcopenia in patients with type 2 diabetes: a cross-sectional study
  Chuan Wang, Chen Jin, Xiaofei Yin, Jidong Liu, Jinbo Liu
  Journal of International Medical Research.2021;[Epub]     CrossRef
• Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
  Hirotatsu Nakaguchi, Yoshinobu Kondo, Mayu Kyohara, Hiromi Konishi, Koji Oiwa, Yasuo Terauchi
  Journal of Diabetes Investigation.2020; 11(6): 1542.     CrossRef
• Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
  Shane P.P. Ryan, Alissa A. Newman, Jessie R. Wilburn, Lauren D. Rhoades, S. Raj J. Trikha, Ellen C. Godwin, Hayden M. Schoenberg, Micah L. Battson, Taylor R. Ewell, Gary J. Luckasen, Laurie M. Biela, Christopher L. Melby, Christopher Bell
  Nutrients.2020; 12(2): 510.     CrossRef
• GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
  Eva W. Iepsen, Christian T. Have, Simon Veedfald, Sten Madsbad, Jens J. Holst, Niels Grarup, Oluf Pedersen, Ivan Brandslund, Jens-Christian Holm, Torben Hansen, Signe S. Torekov
  Cell Reports Medicine.2020; 1(1): 100006.     CrossRef
• Glucagon‐like peptide 1 infusions overcome anabolic resistance to feeding in older human muscle
  Haitham Abdulla, Bethan E. Phillips, Daniel J. Wilkinson, Marie Limb, Tereza Jandova, Joseph J. Bass, Debbie Rankin, Jessica Cegielski, Mariwan Sayda, Hannah Crossland, John P. Williams, Kenneth Smith, Iskandar Idris, Philip J. Atherton
  Aging Cell.2020;[Epub]     CrossRef